Michal Zikan

Summary

Affiliation: Charles University
Country: Czech Republic

Publications

  1. ncbi Novel somatic mutations in the BRCA1 gene in sporadic breast tumors
    Marketa Janatova
    Department of Biochemistry and Experimental Oncology, Charles University in Prague, Prague, Czech Republic
    Hum Mutat 25:319. 2005
  2. ncbi [Hereditary predisposition for the development of breast and ovarian carcinoma]
    M Zikan
    Ustav biochemie a experimentální onkologie 1 LF UK, Praha
    Cas Lek Cesk 143:26-30. 2004
  3. doi Ultrasound-guided tru-cut biopsy of abdominal and pelvic tumors in gynecology
    M Zikan
    Oncogynecologic Center, Department of Obstetrics and Gynecology and, First Medical Faculty and General Teaching Hospital, Charles University, Prague, Czech Republic
    Ultrasound Obstet Gynecol 36:767-72. 2010
  4. ncbi [Molecular characterization of epithelial ovarian borderline tumors with respect to clinical management and prognosis]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 74:427-30. 2009
  5. ncbi [Hereditary susceptibility to endometrial cancer]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 76:176-9. 2011
  6. ncbi [Analyses of LOH and expression in healthy gland, DCIS and invasive breast cancer gland]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 74:102-5. 2009
  7. ncbi [Risk-reducing surgery in women at hereditary risk of gynaecological cancer]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 76:216-21. 2011
  8. ncbi [Molecular biology of preinvasive and invasive breast tumors]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 73:351-5. 2008
  9. ncbi [Inactivation of BRCA1, BRCA2 and p53 genes in sporadic ovarian cancer]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 73:298-302. 2008
  10. ncbi Ultrasonographic appearance of metastatic non-gynecological pelvic tumors
    M Zikan
    Gynecologic Oncology Center, Department of Obstetrics and Gynecology, Charles University, Prague, First Medical Faculty and General Teaching Hospital, Prague, Czech Republic
    Ultrasound Obstet Gynecol 39:215-25. 2012

Detail Information

Publications31

  1. ncbi Novel somatic mutations in the BRCA1 gene in sporadic breast tumors
    Marketa Janatova
    Department of Biochemistry and Experimental Oncology, Charles University in Prague, Prague, Czech Republic
    Hum Mutat 25:319. 2005
    ..The occurrence of inactivating somatic mutations in sporadic breast tumors suggested the role of the BRCA1 gene in tumorigenesis in at least a minor group of patients with non-familial breast cancer...
  2. ncbi [Hereditary predisposition for the development of breast and ovarian carcinoma]
    M Zikan
    Ustav biochemie a experimentální onkologie 1 LF UK, Praha
    Cas Lek Cesk 143:26-30. 2004
    ..Following article presents basic review of the hereditary predisposition to breast and ovarian cancer focusing especially on BRCA1 and BRCA2 genes, which are responsible for almost three-quarters of those hereditary tumours...
  3. doi Ultrasound-guided tru-cut biopsy of abdominal and pelvic tumors in gynecology
    M Zikan
    Oncogynecologic Center, Department of Obstetrics and Gynecology and, First Medical Faculty and General Teaching Hospital, Charles University, Prague, Czech Republic
    Ultrasound Obstet Gynecol 36:767-72. 2010
    ..To analyze the safety, adequacy and accuracy of tru-cut biopsy and to evaluate factors potentially affecting adequacy...
  4. ncbi [Molecular characterization of epithelial ovarian borderline tumors with respect to clinical management and prognosis]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 74:427-30. 2009
    ..To analyze up-to-data knowledge in the field of molecular characterization of epithelial ovarian borderline tumors with respect to clinical management and prognosis...
  5. ncbi [Hereditary susceptibility to endometrial cancer]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 76:176-9. 2011
    ..To present up-to-date knowledge concerning field of hereditary susceptibility to endometrial cancer as a part of hereditary non-polyposis colorectal cancer (Lynch syndrome)...
  6. ncbi [Analyses of LOH and expression in healthy gland, DCIS and invasive breast cancer gland]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 74:102-5. 2009
    ..To characterize molecular pattern differences (LOH and expression) between DCIS and invasive breast cancer...
  7. ncbi [Risk-reducing surgery in women at hereditary risk of gynaecological cancer]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 76:216-21. 2011
    ..To present up-to-date knowledge concerning risk-reducing surgery in carriers of susceptibility mutations among hereditary breast/ovarian cancer syndrome and Lynch syndrome...
  8. ncbi [Molecular biology of preinvasive and invasive breast tumors]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 73:351-5. 2008
    ..To present an overview of molecular characteristics and differences of and between preinvasive and invasive breast tumors...
  9. ncbi [Inactivation of BRCA1, BRCA2 and p53 genes in sporadic ovarian cancer]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 73:298-302. 2008
    ..To analyze loss of heterozygosity (LOH), loss of expression and somatic mutations of BRCA1, BRCA2 and p53 genes in sporadic epithelial ovarian cancer samples...
  10. ncbi Ultrasonographic appearance of metastatic non-gynecological pelvic tumors
    M Zikan
    Gynecologic Oncology Center, Department of Obstetrics and Gynecology, Charles University, Prague, First Medical Faculty and General Teaching Hospital, Prague, Czech Republic
    Ultrasound Obstet Gynecol 39:215-25. 2012
    ..To describe the ultrasound (sonomorphologic and vascular) characteristics of metastatic non-gynecological pelvic tumors, and to identify ultrasound characteristics typical of the most common non-gynecological pelvic tumors...
  11. ncbi Novel complex genomic rearrangement of the BRCA1 gene
    Michal Zikan
    Department of Biochemistry and Experimental Oncology, First Medical School of Charles University, U nemocnice 5, 128 00, Prague, Czech Republic
    Mutat Res 637:205-8. 2008
    ..This rearrangement involves exons 21 and 22 and results in a protein product lacking BRCT domain important for its function...
  12. doi Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer
    Michal Zikan
    Oncogynecologic Center, Department of Obstetrics and Gynecology, Charles University in Prague, First Faculty of Medicine and General University Hospital, Apolinarska 18, Prague 2, Czech Republic
    Clin Transl Oncol 13:652-5. 2011
    ....
  13. ncbi [Transabdominal ultrasound examination in gynecology]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 76:252-7. 2011
    ..To present structured guidelines to transabdominal ultrasound examination in gynecology...
  14. ncbi [Hereditary ovarian cancer]
    M Zikan
    Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 71:246-51. 2006
    ....
  15. ncbi [Ultrasound-guided minimally invasive interventions in gynecologic oncology]
    M Zikan
    Onkogynekologické centrum, Gynekologicko porodnická klinika 1 LF UK a VFN, Praha
    Ceska Gynekol 76:257-61. 2011
    ..To present our experience with ultrasound-guided minimally invasive interventions in gynecologic oncology...
  16. ncbi Mutational analysis of the BRCA1 gene in 30 Czech ovarian cancer patients
    M Zikan
    Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U nemocnice 5, 12853 Prague 2, Czech Republic
    J Genet 84:63-7. 2005
    ..Although large genomic rearragements are known to be relatively frequent in Western European populations, no analyses have been performed in our region yet...
  17. doi Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene
    Ivana Ticha
    Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 128 53, Prague 2, Czech Republic
    Breast Cancer Res Treat 124:337-47. 2010
    ..Implementation of chromosome-specific aCGH could markedly facilitate the design of primers for amplification and sequence analysis of junction fragments, especially in deletions overlapping gene boundaries...
  18. ncbi High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer
    Michal Zikan
    Department of Biochemistry and Experimental Oncology, 1st Faculty of Medicine, Charles University, Prague, U nemocnice 5, 128 53 Prague 2, Czech Republic
    J Genet 86:169-71. 2007
  19. pmc High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area
    Petr Pohlreich
    Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
    Breast Cancer Res 7:R728-36. 2005
    ..The purpose of our study was to estimate the incidence and spectrum of pathogenic mutations in BRCA1/2 genes in high-risk Czech families...
  20. doi High-risk human papillomavirus DNA in paraaortic lymph nodes in advanced stages of cervical carcinoma
    Jiri Slama
    General Teaching Hospital and 1st Medical School of Charles University, Department of Oncogynecology, Apolinarska 18, 128 00 Prague 2, Czech Republic
    J Clin Virol 50:46-9. 2011
    ..Recent studies have confirmed the association of HPV DNA in pelvic lymph nodes in early-stage disease with metastatic involvement and a less favourable prognosis...
  21. doi Abdominal radical trachelectomy in fertility-sparing treatment of early-stage cervical cancer
    David Cibula
    Oncogynecological Center, Department of Obstetrics and Gynecology, General Teaching Hospital, First Medical School, Charles University, Prague, Czech Republic
    Int J Gynecol Cancer 19:1407-11. 2009
    ..Abdominal radical trachelectomy (ART) is one of the fertility-sparing procedures in women with early-stage cervical cancer. In comparison with vaginal radical trachelectomy, the published results of ART are so far limited...
  22. doi Human papillomavirus DNA presence in pelvic lymph nodes in cervical cancer
    Jiri Slama
    Department of Oncogynecology, General Teaching Hospital and 1st Medica School of Charles University, Apolinarska 18, 128 00 Prague 2, Czech Republic
    Int J Gynecol Cancer 20:126-32. 2010
    ....
  23. doi Factors affecting spontaneous voiding recovery after radical hysterectomy
    David Cibula
    Department of Obstetrics and Gynecology, General Teaching Hospital, First Medical School, Charles University, Prague, Czech Republic
    Int J Gynecol Cancer 20:685-90. 2010
    ..The impairment of spontaneous voiding is the most prominent type of morbidity in the early postoperative period after radical hysterectomy. The aim of our work was to evaluate the parameters affecting the recovery of spontaneous voiding...
  24. doi Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis
    David Cibula
    Gynecological Oncology Centre, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
    Gynecol Oncol 127:462-6. 2012
    ..To evaluate the sensitivity of sentinel node (SN) ultrastaging and to define parameters that may reduce the overall false-negative rate in women with early-stage cervical cancer...
  25. doi Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis
    David Cibula
    Gynecological Oncologic Centre, First Faculty of Medicine and General University Hospital, Charles University, Apolinarska 18, Prague 2, Czech Republic
    Expert Rev Anticancer Ther 11:1197-207. 2011
    ..COCs can be considered as an alternative strategy in the chemoprevention of ovarian cancer in BRCA1 mutation carriers who do not accept prophylactic salpingo-oophorectomy above the age of 30 years...
  26. doi Pelvic lymphadenectomy improves survival in patients with cervical cancer with low-volume disease in the sentinel node: a retrospective multicenter cohort study
    Afra Zaal
    Division of Woman and Baby, Department of Gynaecological Oncology, University Medical Center Utrecht, Utrecht, The Netherlands Department of Obstetrics and Gynecology, Gynecological Oncology Centre, First Faculty of Medicine and General University Hospital, Charles University, Prague Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic Institut Claudius Regaud, Toulouse Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique Hopitaux de Paris, European Georges Pompidou Teaching Hospital, Paris, France Jagiellonian University Medical College, Krakow, Poland University Hospital Ostrava, Ostrava, Czech Republic and Center for Gynaecologic Oncology Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    Int J Gynecol Cancer 24:303-11. 2014
    ..In this study, we aimed to describe the value of pelvic lymph node dissection (LND) after sentinel lymph node (SN) biopsy in early-stage cervical cancer...
  27. doi High-risk human papillomavirus DNA in the primary tumor, sentinel, and nonsentinel pelvic lymph nodes in patients with early-stage cervical cancer: a correlation with histopathology
    Jiri Slama
    General Teaching Hospital, Department of Oncogynecology, 1st Medical School of Charles University, Prague 2, Czech Republic
    Int J Gynecol Cancer 19:703-7. 2009
    ..The presence of human papillomavirus (HPV) DNA in histologically negative pelvic nodes is considered a subclinical metastatic spread...
  28. pmc Diagnosis, treatment, and follow-up of borderline ovarian tumors
    Daniela Fischerova
    Gynecological Oncology Center, Department of Obstetrics and Gynecology, Apolinaska 18, 120 00 Prague, Czech Republic
    Oncologist 17:1515-33. 2012
    ..Current literature on this topic leads to a number of controversies that will be discussed thoroughly in this article, with the aim to provide recommendations for the clinical management of these patients...
  29. ncbi Localization of the sentinel node of the upper outer breast quadrant in the axillary quadrants
    David Pavlista
    Department of Oncogynecology, Clinic of Obstetrics and Gynecology, 1st Medical Faculty, Charles University, and General Faculty Hospital, Apolinarska 18, Prague, 12801, Czech Republic
    Ann Surg Oncol 14:633-7. 2007
    ..In such cases, exact knowledge of the topography of the axilla and the most probable location of the SN may be crucial...
  30. pmc AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study
    Fergus J Couch
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 16:1416-21. 2007
    ..In summary, the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers...
  31. pmc RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies
    Antonis C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, CB1 8RN, UK
    Am J Hum Genet 81:1186-200. 2007
    ..Thus, 135G-->C may modify the risk of breast cancer in BRCA2 mutation carriers by altering the expression of RAD51. RAD51 is the first gene to be reliably identified as a modifier of risk among BRCA1/2 mutation carriers...